Serum Testosterone Suppression and Potential for Agonistic Stimulation During Chronic Treatment With Monthly and 3-month Depot Formulations of Leuprolide Acetate for Advanced Prostate Cancer-Reference-Cited by-同舟云学术

Serum Testosterone Suppression and Potential for Agonistic Stimulation During Chronic Treatment With Monthly and 3-month Depot Formulations of Leuprolide Acetate for Advanced Prostate Cancer

Published:2002-09 Issue:3 Volume:168 Page:1001-1004
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Sharifi Roohollah¹,Browneller Robert¹,

Affiliation:

1. From the Department of Urology, University of Illinois at Chicago, Chicago, and TAP Pharmaceutical Products Inc., Lake Forest, Illinois

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference8 articles.

1. Physiological basis for hormonal therapy in carcinoma of the prostate;Walsh;Urol Clin N Amer,1975

2. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer;Sharifi;J Urol,1990

3. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer;Sharifi;Clin Ther,1996

4. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer;Sharifi;Urology,1998

5. Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate;Smith;J Urol,1984

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological and toxicological studies of a novel goserelin acetate extended-release microspheres in rats;Frontiers in Pharmacology;2023-02-21

2. Long-acting injectable PLGA/PLA depots for leuprolide acetate: successful translation from bench to clinic;Drug Delivery and Translational Research;2022-08-17

3. Cardiovascular Toxicity of Androgen Deprivation Therapy;Current Cardiology Reports;2021-07-03

4. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer;Clinical Therapeutics;2019-03

5. Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects;Therapeutic Advances in Urology;2017-11-22